Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
Nov 6, 2024 · Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...
Novo Nordisk shares jump 8% after Wegovy sales beat …
6 days ago · Novo Nordisk on Wednesday reported a third-quarter beat on sales of its blockbuster weight-loss drug Wegovy and narrowed its 2024 full-year growth guidance. 📺 24/7 Chicago news stream: Watch ...
Novo Nordisk's Blockbuster Wegovy Sales Beat Expectations — …
6 days ago · Global News Select Novo Nordisk's Blockbuster Wegovy Sales Beat Expectations — Update ... Novo Nordisk's net profit in the third quarter rose 21% to 27.3 billion kroner, ahead of the 26.79 ...
Novo Nordisk's Ozempic, Wegovy now available after shortages
Oct 30, 2024 · All doses of Novo Nordisk ’s highly popular weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the U.S. Food and Drug...
Latest news - Novo Nordisk
21 October 2024. Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial. Read more.
Novo Nordisk signs deals worth up to $1bn with US biotechs in …
Jan 4, 2024 · Novo Nordisk has signed deals worth up to $1bn with US biotech start-ups developing treatments for obesity and other cardiometabolic diseases, as the Wegovy manufacturer seeks to stay ahead in...
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
Apr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
Novo Nordisk strikes $11bn deal to expand production of weight …
Feb 5, 2024 · Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s...
News Details - Novo Nordisk
Mar 5, 2024 · Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial. Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW.
News details - Novo Nordisk
Mar 8, 2024 · Novo Nordisk's commitment to the obesity and cardiovascular community is a long-term one, and we are investing significantly to build capacity to meet increasing demand. Please visit WegovySupply.com for the latest information.
- Some results have been removed